The Phonetics And Phonology Of Bora Tone

Bora is a Witotoan language spoken in Peru and Colombia. It has an unusual mixed tone/stress system in which L is the specified tone and H the unspecified tone. In this thesis, I describe the underlying tone patterns of noun and verb roots and show how their surface representations change in different phonological environments. I examine noun stems with seven different suffixes and one prefix and verb stems with thirteen different suffixes. Disyllabic noun roots have three surface tone patterns: LH, HL, and LL. Additionally, Bora has a low boundary tone that associates to the right edge of noun phrases. Verb roots are underlyingly toneless. However, verb stems with bound suffixes are assigned one of the following surface tone patterns based on their suffix: LH, HL, or LL. Bora also has a verbal boundary tone that associates to the right edge of verb stems. Affixes may be toneless, have underlying low tones, or have floating low tones. In addition to the underlying tone patterns of morphemes, Bora assigns low tones to stressed syllables. One and two syllable words have stress on the penultimate syllable, while longer words have antepenultimate stress. In Bora, the Obligatory Contour Principle restricts sequences of adjacent low tones. Bora exhibits three responses to OCP conflicts: L Merger, L Deletion, and L Delinking. The choice of OCP resolution is lexically and phonologically determined

Interventions targeting mental health self-stigma: A review and comparison

OBJECTIVE: With growing awareness of the impact of mental illness self-stigma, interest has arisen in the development of interventions to combat it. The present article briefly reviews and compares interventions targeting self-stigma to clarify the similarities and important differences between the interventions. METHOD: We conducted a narrative review of published literature on interventions targeting self-stigma. RESULTS: Six intervention approaches (Healthy Self-Concept, Self-Stigma Reduction Program, Ending Self-Stigma, Narrative Enhancement and Cognitive Therapy, Coming Out Proud, and Anti-Stigma Photo-Voice Intervention) were identified and are discussed, and data is reviewed on format, group-leader backgrounds, languages, number of sessions, primary mechanisms of action, and the current state of data on their efficacy. CONCLUSIONS AND IMPLICATIONS FOR PRACTICE: We conclude with a discussion of common elements and important distinctions between the interventions and a consideration of which interventions might be best suited to particular populations or settings

Concert recording 2013-04-14a

[Track 01]. Moving air / Nigel Westlake -- [Track 02]. New York counterpoint / Steve Reich -- [Track 03]. In motion hand covers bruise / Trent Reznor ; Atticus Ross -- [Track 04]. When it rains / Brad Mehldau -- [Track 05]. Born to be wild / David Lang -- [Track 06]. Cheating, lying, stealing / David Lang -- [Track 07]. Two instrumental rounds in snaketime / Moondog -- [Track 08]. Motown metal / Michael Daughterty

Keeping hunting bans on target

Letter: The U.K. government has proposed an Animals Abroad Bill, which would ban the import of hunting trophies. However, this ban is not clearly based on any deontological moral position or system of virtue ethics (Bichel,2021) because domestic trophy hunting and hunting trophy exports will still be allowed. Nevertheless, the U.K. Government claims its import ban will “disincentivize trophy hunting...and send a positive signal internationally.

Solid State Proton Spin Relaxation and Methyl and \u3ci\u3et\u3c/i\u3e-Butyl Reorientation

We have measured the temperature T and Larmor frequency ω/2π dependence of the proton spin‐lattice relaxation rate R in solid 1‐hydroxy‐2,4,6‐tri‐butylbenzene. The data is interpreted in terms of the rotational motion of the t‐butyl groups and their constituent methyl groups. Our data is much more extensive than a previous report [J. Yamauchi and C. A. McDowell, J. Chem. Phys. 75, 1051 (1981)] resulting in a revised dynamical model and considerably larger rotational barriers. Interesting thermal history effects are discussed

Analysis of SARS-CoV-2 Emergent variants following AZD7442 (tixagevimab/cilgavimab) for early outpatient treatment of COVID-19 (TACKLE trial)

Introduction: AZD7442 (tixagevimab/cilgavimab) comprises neutralising monoclonal antibodies (mAbs) that bind to distinct non-overlapping epitopes on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. Viral evolution during mAb therapy can select for variants with reduced neutralisation susceptibility. We examined treatment-emergent SARS-CoV-2 variants during TACKLE (NCT04723394), a phase 3 study of AZD7442 for early outpatient treatment of coronavirus disease 2019 (COVID-19). Methods: Non-hospitalised adults with mild-to-moderate COVID-19 were randomised and dosed ≤ 7 days from symptom onset with AZD7442 (n = 452) or placebo (n = 451). Next-generation sequencing of the spike gene was performed on SARS-CoV-2 reverse-transcription polymerase chain reaction-positive nasopharyngeal swabs at baseline and study days 3, 6, and 15 post dosing. SARS-CoV-2 lineages were assigned using spike nucleotide sequences. Amino acid substitutions were analysed at allele fractions (AF; % of sequence reads represented by substitution) ≥ 25% and 3% to 25%. In vitro susceptibility to tixagevimab, cilgavimab, and AZD7442 was evaluated for all identified treatment-emergent variants using a pseudotyped microneutralisation assay. Results: Longitudinal spike sequences were available for 461 participants (AZD7442, n = 235; placebo, n = 226) and showed that treatment-emergent variants at any time were rare, with 5 (2.1%) AZD7442 participants presenting ≥ 1 substitution in tixagevimab/cilgavimab binding sites at AF ≥ 25%. At AF 3% to 25%, treatment-emergent variants were observed in 15 (6.4%) AZD7442 and 12 (5.3%) placebo participants. All treatment-emergent variants showed in vitro susceptibility to AZD7442. Conclusion: These data indicate that AZD7442 creates a high genetic barrier for resistance and is a feasible option for COVID-19 treatment

Analysis of SARS-CoV-2 Emergent Variants Following AZD7442 (Tixagevimab/Cilgavimab) for Early Outpatient Treatment of COVID-19 (TACKLE Trial)

Introduction: AZD7442 (tixagevimab/cilgavimab) comprises neutralising monoclonal antibodies (mAbs) that bind to distinct non-overlapping epitopes on the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. Viral evolution during mAb therapy can select for variants with reduced neutralisation susceptibility. We examined treatment-emergent SARS-CoV-2 variants during TACKLE (NCT04723394), a phase 3 study of AZD7442 for early outpatient treatment of coronavirus disease 2019 (COVID-19). // Methods: Non-hospitalised adults with mild-to-moderate COVID-19 were randomised and dosed ≤ 7 days from symptom onset with AZD7442 (n = 452) or placebo (n = 451). Next-generation sequencing of the spike gene was performed on SARS-CoV-2 reverse-transcription polymerase chain reaction-positive nasopharyngeal swabs at baseline and study days 3, 6, and 15 post dosing. SARS-CoV-2 lineages were assigned using spike nucleotide sequences. Amino acid substitutions were analysed at allele fractions (AF; % of sequence reads represented by substitution) ≥ 25% and 3% to 25%. In vitro susceptibility to tixagevimab, cilgavimab, and AZD7442 was evaluated for all identified treatment-emergent variants using a pseudotyped microneutralisation assay. // Results: Longitudinal spike sequences were available for 461 participants (AZD7442, n = 235; placebo, n = 226) and showed that treatment-emergent variants at any time were rare, with 5 (2.1%) AZD7442 participants presenting ≥ 1 substitution in tixagevimab/cilgavimab binding sites at AF ≥ 25%. At AF 3% to 25%, treatment-emergent variants were observed in 15 (6.4%) AZD7442 and 12 (5.3%) placebo participants. All treatment-emergent variants showed in vitro susceptibility to AZD7442. // Conclusion: These data indicate that AZD7442 creates a high genetic barrier for resistance and is a feasible option for COVID-19 treatment